Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to support the discovery and development of therapies for patients with triple-negative breast cancer and the most common form of non-small cell lung cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: $20.0 million
Deal Type: Collaboration May 28, 2024